The Iams Company

Alimentary Health Limited

The Procter Gamble Company

University College Cork

Enterprise Ireland

Mars, Incorporated

Teagasc, the Agriculture and Food Development Authority

Enterprise Ireland (trading As Bioresearch Ireland)

John Kevin Collins

Liam Diarmuid O'Mahony

Barry Kiely

Gregory Dean Sunvold

Gary Mitchell Davenport

Mark Alan Tetrick

Thomas William-Maxwell Boileau

Michael Anthony Ceddia

Robert Jason Vickers

Fergus Shanahan

Gerald Christopher O'Sullivan

Barry Pius Kiely

Liam Diarmuid O'mahony

Ker-Sang Chen

Fangyi Luo

Ross Peter Phillipson

Reynolds Paul Ross

Marian Mary Geraldine O'Sullivan

Catherine Gerardine Stanton

Gerald Francis Fitzgerald

Gerardine Mary Thornton

Liam O'mahony

Gerald Christopher O'sullivan

Fangi Luo

Marian Mary Geraldine O'SULLIVAN

According to the invention there is provided a strain of lactic acid bacteria of the speciesobtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising theof the present invention are also provided.

Canine probiotic bifidobacterium pseudolongum

Method of treating diarrhea in a canine

According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.

[object Object]

Canine probiotic bifidobacteria globosum

Novel methods of determining efficacy of a treatment of inflammatory diseases of the bowel in mammals are provided. The methods are of use in screening and determining the efficacy of treatments of inflammatory diseases of the bowel, and for determining the efficacy response of individual sufferers of inflammatory diseases of the bowel to a given regime. Kits for carrying out the method are also provided.

Methods of determining efficacy of treatments of diseases of the bowel

According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteriaobtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteriaof the present invention are also provided.

Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium

Methods of determining efficacy of treatments of inflammatory diseases of the bowel

According to the invention there is provided a strain of lactic acid bacteria of the genusobtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising theof the present invention are also provided.

Astrain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.

A strain ofisolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.

Bifidobacterium in the treatment of inflammatory disease

A strain ofisolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by, growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including, including methocillin resistant(MRSA), and, but does not inhibit many closely related. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties.

A process for the manufacture of a probiotic cheese, such as Cheddar cheese, comprises adding a 0.0-5.5% inoculum of a strain of, which is non-pathogenic, acid and bile tolerant and adherent to human epithelial cells, as a starter adjunct to cheese milk, saidstrain being capable of growing during the ripening phase to a level of 10cfu/g or greater. Thestrains are found to grow and proliferate to high cell numbers (in excess of 10cfu/g) in the cheese over eight months of ripening, even when added at a relatively low inoculum. The presence of thestrains is found to have negligible effects on cheese composition, flavor and aroma.

Process for the manufacture of probiotic cheese

Growing community of inventors

Cork, Ireland

John Kevin Collins